H. Joachim Deeg

References 1. McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659–68. 2. Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015;29:2126–33.

Andrew Schorr: Greetings. It's Andrew Schorr from Patient Power. I am very excited that we're doing this program for the MPN community about really weighing decisions about transplant. Joining us from Fair Lawn, New Jersey, is my friend Ron Roth, and joining us from Seattle, Washington, is Dr. Joaquim Deeg, who's one of the foremost physicians related to transplant in the world.

The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders has continued to grow worldwide.1-3 Great progress has been made in overcoming HLA/immunologic barriers, but nondonor barriers to HCT persist.4 This represents a major unmet need because HCT is not accessible to everyone who would benefit from it.5 In ethical terms, this is an unacceptable failure of distributive justice.6 In this commentary, we highlight...